Medication info
H-Prasole Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

H-Prasole Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›43.38mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201507775 · Approved 2015.11.19 · Insurance code 642003670

Summary

Main use
Treatment and prevention of acid-related disorders (reflux, Zollinger-Ellison syndrome, etc.), ulcers, and NSAID-induced gastrointestinal disorders
Who uses it
Adults · Children
Adult dosage
Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Concomitant antibiotic therapy for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should be continued while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses of 80 mg or more per day should be divided into two doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of acid-related disorders (reflux, Zollinger-Ellison syndrome, etc.), ulcers, and NSAID-induced gastrointestinal disorders

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive esophagitis as well as symptom relief. It is also effective in the treatment of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection and in preventing their recurrence. It helps in the short-term treatment of upper gastrointestinal symptoms caused by non-steroidal anti-inflammatory drug administration and in the treatment and prevention of gastric ulcers as well as duodenal ulcers. It is used as maintenance therapy following induction for the treatment of Zollinger-Ellison syndrome and for the prevention of rebleeding from gastric or duodenal ulcers. It is widely used for the treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric or duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Concomitant antibiotic therapy for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should be continued while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses of 80 mg or more per day should be divided into two doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is necessary. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be used in patients with specific allergic reactions. In particular, it should be avoided in those with hypersensitivity to this medication, its components, or benzimidazoles. Furthermore, when used in conjunction with antibiotics such as amoxicillin or clarithromycin for the eradication of Helicobacter pylori, this medication should not be used in patients allergic to these antibiotics. Patients taking specific heart-related medications or antiviral agents, as well as breastfeeding women, should not take this medication. This medication can cause various side effects, with common symptoms including headaches, abdominal pain, and diarrhea. Rarely, blood abnormalities, allergic reactions, liver dysfunction, and severe skin reactions can occur, so any abnormal symptoms should prompt immediate consultation with a physician. Long-term use may lead to electrolyte imbalances such as decreased magnesium levels; therefore, regular testing is necessary. Moreover, this medication lowers gastric acidity, which may slightly increase the risk of bacterial infections in the stomach, so if diarrhea persists, medical personnel should be informed. This medication may interact with other drugs, so it is essential to inform your doctor or pharmacist especially if you are taking anticoagulants, antibiotics, antiviral drugs, or anticonvulsants. Caution is required as there is a risk of side effects due to changes in blood concentration when used with other medications. If using this medication during pregnancy, careful consideration should be given, and it is safest not to take it while breastfeeding. In cases of overdose, there is no specific antidote, so treatment based on symptoms and general management is required, and it should be stored in a safe place out of reach of children. When using this medication, it is important to administer the minimum dose and duration as directed by a physician and to consult a specialist immediately if any abnormal symptoms occur.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Reye's syndrome, acute generalized exanthematous pustulosis, eosinophilia, drug reactions with systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reactions, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, upper abdominal pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, worsening arthritis, arthropathy, cramps, fibromyalgia, hernia, polymyalgia rheumatica, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorders, tremors, dizziness, visual field defect, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, altered olfaction, taste loss, taste disturbance, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric adenomatous polyp, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, asthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to avoid exposure to air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.